Analysts Q&A Summary:
1) Chris Schott from JPMorgan:
– The question: Chris asked about the increase in guidance for SKYRIZI and RINVOQ and the competitive landscape, particularly mentioning Tremfya in IBD. He also inquired about the future outlook for HUMIRA.
– The response: Scott provided a breakdown of the increase in guidance, attributing portions to different indications. Jeff highlighted the strong performance of SKYRIZI and RINVOQ and discussed the dynamics of competition, indicating confidence in their profiles. On HUMIRA, higher than expected erosion from biosimilar competition was noted, impacting future sales guidance.
2) Terence Flynn from Morgan Stanley:
– The question: Terence asked about the potential impact of tariffs on inventory and any changes in IP domiciling. He also inquired about future steps for the Amylin program, specifically regarding dosing strategies.
– The response: Rob discussed AbbVie’s manufacturing footprint and potential strategies for mitigating tariff impacts. Addressing IP, Scott mentioned AbbVie’s competitive tax profile. Rupal detailed the dosing study for the Amylin program, emphasizing future study phases and potential combinations.
3) Carter Gould from Cantor:
– The question: Carter asked about drug pricing and the potential impact of co-administering Bon T and BOTOX.
– The response: Rob reiterated AbbVie’s stance on balanced policies for innovation and affordability. Jeff explained Bon T’s market potential, including its ability to stimulate market growth and the strategy for its combination with Botox.
4) Courtney Breen from Bernstein:
– The question: Courtney questioned AbbVie’s inventory levels amid tariff discussions and asked for more details on Bon T’s pricing strategy.
– The response: Rob avoided speculation due to lack of policy details, while Jeff assured that rigorous pricing analysis would determine Bon T’s pricing, considering its role in market stimulation and potential value addition.
5) Mohit Bansal from Wells Fargo:
– The question: Mohit inquired about the strategy for Gupras an Amylin analog, specifically regarding its use as a monotherapy versus in combination with GLP-1.
– The response: Rupal highlighted the potential of Amylin as a monotherapy due to its tolerance profile and its attractiveness for combination due to a neutral pH formulation.
6) Steve Scala from TD Cowen:
– The question: Steve asked for updates on mirabegron and how AbbVie assesses its outside-U.S. footprint, including plant utilization, amid policy changes.
– The response: Rupal outlined a stepwise approach for mirabegron to explore higher dosing. Rob articulated the thoughtful balance in manufacturing strategy between U.S. and international locations, citing Assurance of Supply and tax considerations.
7) Dave Risinger from Leerink Partners:
– The question: Dave inquired about risks from government actions affecting biopharma and potential trade policy shifts.
– The response: Rob emphasized active engagement with government affairs to support a balanced policy approach. Scott clarified that trade policy shifts discussed pertained specifically to the pharmaceutical sector tariffs.
8) Vamil Divan from Guggenheim Securities:
– The question: Vamil inquired about tariffs’ impact on the aesthetics business and whether China tariffs are included in guidance.
– The response: Scott confirmed that tariffs on the aesthetics business were modest and accounted for in guidance, while Jeff indicated stable market share in China.
Sentiment Score Distribution Table:
| Analyst Name | Firm Name | Sentiment Score (1-10) |
|—————–|——————|————————|
| Chris Schott | JPMorgan | 8 |
| Terence Flynn | Morgan Stanley | 7 |
| Carter Gould | Cantor | 8 |
| Courtney Breen | Bernstein | 7 |
| Mohit Bansal | Wells Fargo | 8 |
| Steve Scala | TD Cowen | 7 |
| Dave Risinger | Leerink Partners | 7 |
| Vamil Divan | Guggenheim | 7 |
These scores reflect the overall positive tone of the management’s responses, providing data-driven answers and strategic reassurance related to growth and market prospects.